The efficacies of tigecycline and ceftazidime against fatal pneumonia in rats caused by an extended-spectrum β-lactamase (ESBL)-positive Klebsiella pneumoniae strain or its wild-type (WT) progenitor were compared. Ceftazidime at 12.5 or 50 mg/kg of body weight twice daily (b.i.d.) was effective (50% or 100% rat survival) in pneumonia caused by the WT isolate but unsuccessful (100% rat mortality) in pneumonia caused by the ESBL-positive variant. In contrast, tigecycline at 6.25, 12.5, or 25 mg/kg b.i.d. showed dosage-dependent efficacy up to 100% rat survival irrespective of the ESBL character of the infecting organism. Copyright

dx.doi.org/10.1128/AAC.01154-12, hdl.handle.net/1765/63182
Antimicrobial Agents and Chemotherapy
Department of Medical Microbiology and Infectious Diseases

Goessens, W.H.F, Mouton, J.W, ten Kate, M.T, Sorgel, F, Kinzig, M, & Bakker-Woudenberg, I.A.J.M. (2013). The therapeutic effect of tigecycline, unlike that of ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats. Antimicrobial Agents and Chemotherapy, 57(1), 643–646. doi:10.1128/AAC.01154-12